Janssen Research & Development
1400 McKean Road
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
27 articles with Janssen Research & Development
Janssen R&D's New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Janssen R&D today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX had a manageable safety profile and a 12 percent rate of infusion reactions in patients with relapsed or refractory multiple myeloma.
Janseen Biotech Release: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible
Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.
Sustained Benefit in Patients With Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 1/2 -Year Follow-Up Data of IMBRUVICA (ibrutinib)
The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.
Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
This application is based on data from the landmark COMPASS study, the only randomized trial to investigate a Factor Xa inhibitor for preventing major CV events in this population.
Janssen's New Real-World Analysis Shows INVOKANA (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.
Janssen R&D's INVOKANA (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure and renal outcomes in each of the primary and secondary prevention groups.
Janssen's New Phase II Data Show Treatment With TREMFYA (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
According to findings presented at the 2017 ACR/ARHP Annual Meeting, more than 70 percent of patients receiving TREMFYA 100 mg subcutaneous injections achieved at least a 20 percent improvement in signs and symptoms of disease using observed data at week 56.
Janssen R&D's STELARA (ustekinumab) Shows Positive Results In Treatment of Systemic Lupus Erythematosus in Phase II Trial
The study met the primary endpoint, with a significantly higher proportion of patients in the STELARA group showing improvements in lupus disease activity as measured by the SLE Responder Index (SRI)-4 response at week 24, compared with patients receiving placebo.
Janssen R&D's INVOKANA (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Pot...
11/3/2017The renal analyses showed that compared to placebo, canagliflozin successfully reduced the risk of kidney disease progression.
ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, With New Data on DARZALEX (Daratumumab), IMBRUVICA (Ibrutinib) and Other Compounds From Robust Portfolio
New data for the immunotherapy DARZALEX (daratumumab) and first-in-class BTK inhibitor IMBRUVICA (ibrutinib) are among eight oral presentations from Janssen Research & Development, LLC, to be featured at the 59th American Society of Hematology Annual Meeting & Exhibition taking place December 9-12, in Atlanta, GA.
BioMed X announced today a collaboration agreement with Janssen Research & Development to foster early-stage preclinical biomedical research and development projects.
Janssen R&D Submits Supplemental New Drug Application (sNDA) To U.S. FDA Seeking New Indication For Invokana (CANAGLIFLOZIN) To Reduce The Risk Of Major Adverse Cardiovascular Events (MACE) Based On Landmark Canvas Program
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy
Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma
Janssen R&D Partners With University of Pennsylvania And Castleman Disease Collaborative Network To Launch First Global Patient Registry For Castleman Disease
Janssen R&D To Present Data From Six Compounds Including Daratumumab And Ibrutinib At The 2016 ASCO Annual Meeting
Medivir Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C
Janssen Research & Development To Showcase Growing Portfolio With More Than 40 Data Presentations At The 2015 American Society of Hematology Annual Meeting
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent